MDXG
NASDAQ · Biotechnology
Mimedx Group Inc
$4.12
-0.05 (-1.20%)
Open$4.16
Previous Close$4.17
Day High$4.27
Day Low$4.08
52W High$8.21
52W Low$4.70
Volume—
Avg Volume1.07M
Market Cap705.69M
P/E Ratio14.53
EPS$0.32
SectorBiotechnology
Analyst Ratings
Strong Buy
11 analysts
Price Target
+486.2% upside
Current
$4.12
$4.12
Target
$24.15
$24.15
$19.42
$24.15 avg
$35.38
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 432.70M | 372.82M | 190.63M |
| Net Income | 50.20M | 38.93M | 27.70M |
| Profit Margin | 11.6% | 11.0% | 14.5% |
| EBITDA | 66.92M | 54.77M | 34.17M |
| Free Cash Flow | — | — | 29.04M |
| Rev Growth | +16.1% | +16.1% | +8.9% |
| Debt/Equity | 0.07 | 0.07 | 0.66 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $207.18 | +0.96% | 166.6 | 397.77B |
| AMGN | Amgen Inc | $353.93 | +1.58% | 24.4 | 188.06B |
| GILD | Gilead Sciences Inc | $138.26 | +0.11% | 20.0 | 170.34B |
| VRTX | Vertex Pharmaceuticals Inc | $454.97 | +1.42% | 29.2 | 115.53B |
| REGN | Regeneron Pharmaceuticals | $749.47 | +1.05% | 17.9 | 80.50B |
| ALNY | Alnylam Pharmaceuticals Inc | $328.70 | +6.70% | 139.7 | 43.84B |